comparemela.com

Latest Breaking News On - Fondazione policlinico gemelli - Page 1 : comparemela.com

Study Shows Feasibility of IO Maintenance After IO/VEGF TKI Response in Previously Untreated Metastatic ccRCC

Interrupting combination treatment with axitinib and avelumab and switching to avelumab maintenance after a response at 36 weeks led to a decrease in treatment-related toxicities and delayed tumor progression in previously untreated patients with metastatic clear cell renal cell carcinoma.

Rome
Lazio
Italy
Fondazione-policlinico-gemelli
Roberto-iacovelli
Database-consortium
International-metastatic
Axitinib
Avelumab
Avelumab-maintenance
Metastatic-clear-cell-renal-carcinoma
Tidea-trial-

Karyopharm Announces New Preliminary Data in Overall Survival (OS) in Selinexor-Treated Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer as Part of Pre-Specified Exploratory Subgr

Karyopharm Announces New Preliminary Data in Overall Survival (OS) in Selinexor-Treated Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer as Part of Pre-Specified Exploratory Subgr
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Boston
Massachusetts
United-states
Singapore
Germany
South-korea
Italy
Rome
Lazio
Canada
Austria
Hong-kong

Predictive factors of surgical complications after pelvic exenteration for gynecological malignancies: a large single-institution experience.

To evaluate pre-operative predictors of early (<30 days) severe complications (grade Dindo 3+) in patients with gynecological malignancy submitted to pelvic exenteration (PE).We retrospectively analyzed 129 patients submitted to surgery at Fondazione Policlinico Gemelli between 2010 and 2019. We included patients affected by primary or recurrent/persistent cervical, endometrial, or vulvar/vaginal cancers. Post-operative complications were graded

Japan
Fondazione-policlinico-gemelli
Asian-society-of-gynecologic-oncology
Korean-society-of-gynecologic-oncology
Japan-society-of-gynecologic-oncology
Gynecologic-oncology
Korean-society
Japan-society

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.